chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I never got a fever but I did have body and joint aches. That started the first day. I went to Emergent Center August 25th. I had headache and congestion and just felt punky. No treatment - I just treated it like a flu bug - I drank a lot of liquids and rested.  On 9/2/2021 - I had a monoclonal infusion and that was day # 9 and that really turned me around. By day 11, Saturday, I was feeling much better.
Shaking activity, questioned for seizure, 48-72 hours, post vax.
Bad reaction that sent him to the hospital; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Bad reaction that sent him to the hospital) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Bad reaction that sent him to the hospital). At the time of the report, VACCINATION COMPLICATION (Bad reaction that sent him to the hospital) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications and treatment information were reported.
4/12/21 12:30 pm began to feel fatigued, face felt flushed. No fever. Fatigue increased more in the evening.   4/13/21 2:30 am awoke and found entire face swollen and slight tingle in lips.  Took Loratadine, Metoprolol and Triamterene/HCTZ and went back to bed.  Awoke at 5 am, swelling better, but not gone. Still very puffy above and below eyes. Felt fatigue, no fever, went to work. Felt better by lunch time, swelling almost gone. 4/14/21 Slight sore throat, slight fatigue, no swelling.
This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient didn't get the second in 4 weeks and is 6 months past the first) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Not Provided) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient didn't get the second in 4 weeks and is 6 months past the first). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient didn't get the second in 4 weeks and is 6 months past the first) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided.   Treatment information was not  provided.
Left side, jaw is sore. Pretty steady. Also wife has same feeling. She got her shot right after me.Day 3. Jaw still sore. Staring ibuprofen.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient received bnt162b2 (BNT162B2), administration date 09Apr2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN JAW (non-serious), outcome "unknown", described as "Left side, jaw is sore. Pretty steady. Also wife has same feeling. She got her shot right after me.Day 3. Jaw still sore. Staring ibuprofen.".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021402449 Same reporter/drug/event, diff pt
Patient fainted and stated troubled breathing  multiple times once regained consciousness. Epi Pen administered and symptoms resolved within 10 minutes.  Patient did not need further medical attention.
Information has been received from a medical assistant referring to a patient of unknown age and gender. Information about concurrent condition, concomitant medication and medical history was not provided. On 07-FEB-2019, the patient was vaccinated with improperly stored PEDVAXHIB (1 injection, via intramuscular, lot # reported as: R0123571, expiration date: 19-MAR-2021; strength and anatomical location were not reported) for prophylaxis. No adverse effect was reported. The PEDVAXHIB was exposed to 0 degree Celsius for 45 minutes. There was no previous temperature excursion. The data logger was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1902USA008818: US-009507513-1903USA006922: US-009507513-1903USA006923: US-009507513-1903USA006924: US-009507513-1903USA006925: US-009507513-1903USA006926: US-009507513-1903USA006927: US-009507513-1903USA006928: US-009507513-1903USA006929: US-009507513-1903USA006930: US-009507513-1903USA006931: US-009507513-1903USA006932: US-009507513-1903USA006933: US-009507513-1903USA006934: US-009507513-1903USA006935: US-009507513-1903USA006936: US-009507513-1903USA006937: US-009507513-1903USA006938: US-009507513-1903USA006939: US-009507513-1903USA006940: US-009507513-1903USA006941: US-009507513-1903USA006943: US-009507513-1903USA006944: US-009507513-1903USA006945: US-009507513-1903USA006946: US-009507513-1903USA006947: US-009507513-1903USA006948: US-009507513-1903USA006949: US-009507513-1903USA006950.
Pt recvd MMR vax & w/in 24 hrs to 48 hrs following vax pt devel t013 w/enlargement of the occipital lymph nodes; sx resolved the next day; 10 to 14 days following vax devel small pinpoint rash primarily on chest & trunk;
Presented with left-sided chest pain consistent with elevated troponin caused by NSTEMI; incidental COVID-19 finding but asymptomatic
Member had flu-like symptoms with malaise and a sore arm for 3 days.  He missed work for 3 days.  He was given Darvocet and took Zithromax.
Patient experienced light headedness and may have faited. He hit nose on immunization table, causing it to bleed.  pt was fine after about 5 minutes and declined treatment or ems care.  we continued to monitor for 20 minutes and pt left with mother needing no other care or assistance.
Tingly sensations all over body on and off,  like crawling feeling for 12 plus hours. No shortness of breathe noted or blisters/break outs.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Feb-2021 at 9:28 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 14-Feb-2021 at 9:28 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 59.65.  Concomitant products were not provided.  On 14-Feb-2021, Excursion time was 09 AM, 10 AM and 11 AM, temperature was 32 respectively and at 02 PM and 03 PM, temperature was 35 respectively, total doses given for the day was 162, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 09-Feb-2021, vial was moved to clinic on 13-Jan-2021. 30 vials were sent to clinic. Vaccine BUD date was 10-Mar-2021.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
BLOOD PRESSURE ABNORMAL; CHEST PAIN (BELOW THE BREAST) AFTER AN HOUR OF VACCINATION; AFTER AN HOUR OF VACCINATION REDNESS OF FACE AND CHEST; FEVER; FATIGUED; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018 expiry: UNKNOWN) dose was not reported, administered on 08-MAR-2021 08:00:00 for prophylactic vaccination. No concomitant medications were reported.  On 09-MAR-2021, the patient experienced blood pressure abnormal, chest pain (below the breast) , after an hour of vaccination redness of face and chest, had fever and was fatigued. Laboratory data included: Blood pressure (NR: not provided) 185/88 (units unspecified), 177/80 (units unspecified), and Body temperature (NR: not provided) 98.9. Laboratory data (dates unspecified) included: Blood pressure (NR: not provided) 141/78 (units unspecified). Treatment medications (dates unspecified) included: ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from blood pressure abnormal, chest pain, after an hour of vaccination redness of face and chest, and fever, and had not recovered from fatigued. The reporter considered the causality between covid-19 vaccine ad26.cov2.s and blood pressure abnormal, chest pain (below the breast), redness of face and chest, fever, fatigued was possible. Company causality between covid-19 vaccine ad26.cov2.s and blood pressure abnormal, chest pain, redness of face and chest, fever, fatigued was possible. This report was serious (Other Medically Important Condition).; Sender's Comments: V0 :20210317973-COVID-19 VACCINE AD26.COV2.S -Blood Pressure Abnormal . This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event.
3/27/2023 in the afternoon I got a tickle in my throat. Just the right side. I had trouble clearing my throat and my right ear felt full. I got a low-grade fever, 100. The next day, 3/28, I got a cough, the fever hit 102.3, chills, and a headache. I felt like I had lots of head congestion. Phone visit with doctor who prescribed PAXLOVID and advised to use DAYQUIL and NYQUIL. For the next week and a half, symptoms persisted, but gradually diminished. Felt recovered by 4/9, with fatigue being the final symptom to resolve.
extremely dizzy; Not able to stand up unless she was grabbing some furniture; Swing motion that is taking different nodes of reaction; Headache; Received second dose 11 days after the first dose; Same symptoms of the first dose (chills, body ache, arm was sore); Same symptoms of the first dose (chills, body ache, arm was sore); Same symptoms of the first dose (chills, body ache, arm was sore); This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (extremely dizzy), GAIT INABILITY (Not able to stand up unless she was grabbing some furniture), MOTION SICKNESS (Swing motion that is taking different nodes of reaction), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 11 days after the first dose) and PAIN (Same symptoms of the first dose (chills, body ache, arm was sore)) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 010M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Cancer, Allergy to antibiotic (Amoxicillin), Drug allergy and Vertigo. Concomitant products included CARFILZOMIB (KYPROLIS) for Cancer, POTASSIUM, CALCIUM and VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 11 days after the first dose), PAIN (Same symptoms of the first dose (chills, body ache, arm was sore)), PAIN IN EXTREMITY (Same symptoms of the first dose (chills, body ache, arm was sore)) and CHILLS (Same symptoms of the first dose (chills, body ache, arm was sore)). On 15-Mar-2021, the patient experienced DIZZINESS (extremely dizzy), GAIT INABILITY (Not able to stand up unless she was grabbing some furniture), MOTION SICKNESS (Swing motion that is taking different nodes of reaction) and HEADACHE (Headache). On 13-Mar-2021, PAIN (Same symptoms of the first dose (chills, body ache, arm was sore)), PAIN IN EXTREMITY (Same symptoms of the first dose (chills, body ache, arm was sore)) and CHILLS (Same symptoms of the first dose (chills, body ache, arm was sore)) had resolved. At the time of the report, DIZZINESS (extremely dizzy), GAIT INABILITY (Not able to stand up unless she was grabbing some furniture), MOTION SICKNESS (Swing motion that is taking different nodes of reaction), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received second dose 11 days after the first dose) and HEADACHE (Headache) outcome was unknown. Not Provided          Patient's concomitant medication also included Celexa for cancer.   Patient had a shutter shoulder on right arm and hence took the vaccine on left arm. No treatment information was provided.   This case was linked to MOD-2021-049908 (Patient Link).
In office with 14 yr & 16 yr siblings.  All were scheduled for COVID 19 vaccine #2.  Patient is 11 yr & 9 mo of age.  COVID 19 over 12 vaccine was given  to patient instead of 5-11 yr dose.  Contacted Pfizer Medical Department for advice.  Spoke with Mom  at 4:00 pm reported no issues.
Patient received a vaccine past the 30 day storage on the refrigerator; Dose administered after 30-day Use By Date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Patient received a vaccine past the 30 day storage on the refrigerator) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L21A) for COVID-19 vaccination.     Patient had Statin allergy, Amlodipine Allergy and Ezetimibe Allergy.  It was unknown if the patient tested positive/negative for COVID-19 within last month.  Concurrent medical conditions included Drug allergy, Diabetes, Drug allergy and Drug allergy. Concomitant products included TRIAMCINOLONE, ESCITALOPRAM, IBUPROFEN, LORATADINE, ASA, LORAZEPAM, PRAZOSIN, ALBUTEROL SULFATE, BENZONATATE, FLUTICASONE, LOSARTAN, NIFEDIPINE and MUPIROCIN for an unknown indication.    On 06-Apr-2022 at 9:31 AM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2022 at 9:31 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Patient received a vaccine past the 30 day storage on the refrigerator). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Patient received a vaccine past the 30 day storage on the refrigerator) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient was not COVID-19 positive within last month.  The number of doses/vials was 36.  On 25-Feb-2022, the vial was initially stored in the refrigerator.  The vial did not undergo any temperature excursions.  Patient did not experience any side effects at the time of report.  No Treatment information was reported.
12 mo girl had 1 year old vaccines mth, no signs of illness.  Vaccines given in morning.  Developed fever in evening up to 104 F, had febrile seizure increased 1 minute in length.  Seen in ER.  Doing well the next day.  Signs of first tooth coming through.
This spontaneous report was received from a registered nurse and refers to an 18 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 14-JUL-2017, the patient was vaccinated with an improperly stored VARIVAX at a dose of 0.5 (units not specified) from lot # N012132 with expiry date: 17-APR-2019 (dose number, route, anatomical location and site of administration were not reported) for prophylaxis. Concomitant medications included a properly stored sterile diluent (manufacturer unknown). The administered dose of vaccine was stored in the temperature between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 20 hours and in the temperature between 15 degrees Fahrenheit and 46 degrees Fahrenheit for 6 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No additional information was provided. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1707USA004945.
injection site pruitus; injection site rash; A big red spot around the injection site; Skin is so warm that when they measured it was 100 degrees; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INJECTION SITE PRURITUS (injection site pruitus), INJECTION SITE RASH (injection site rash), VACCINATION SITE ERYTHEMA (A big red spot around the injection site) and PYREXIA (Skin is so warm that when they measured it was 100 degrees) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     Concurrent medical conditions included Breast cancer.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced INJECTION SITE PRURITUS (injection site pruitus), INJECTION SITE RASH (injection site rash), VACCINATION SITE ERYTHEMA (A big red spot around the injection site) and PYREXIA (Skin is so warm that when they measured it was 100 degrees). At the time of the report, INJECTION SITE PRURITUS (injection site pruitus), INJECTION SITE RASH (injection site rash), VACCINATION SITE ERYTHEMA (A big red spot around the injection site) and PYREXIA (Skin is so warm that when they measured it was 100 degrees) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, Body temperature: 100 f High.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 26-Apr-2021: Non significant follow up received on 26-APR-2021, no new information; Sender's Comments: Based on the current available information and temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. Fever, injection site rash, injection site erythema and injection site pruritus are consistent with the product safety profile
Chills and seizure like activity, fever, body aches, severe head ache, nausea, extreme thirst,
past away a few days after getting the Moderna first dose; This spontaneous case was reported by a physician and describes the occurrence of DEATH (past away a few days after getting the Moderna first dose) in a 98-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Leukemia.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Death occurred on an unknown date The cause of death was not reported. It is unknown if an autopsy was performed.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   no treatment and concomitant medications reported. Company Comment: This case concerns a 98-year-old, male patient with relevant medical history of hypertension, atrial fibrillation, heart catherization, leukemia, who experienced the unexpected event of Death. The event occurred approximately few hours after the first dose of mRNA-1273 (Moderna covid-19 vaccine). The rechallenge was not applicable, as the event happened after the first dose. Though limited information provided such as circumstances surrounding death, cause of death, and autopsy precludes a complete medical and causal assessment of this case; however, this patient's advanced age and multiple underlying medical conditions remains a confounder. The benefit-risk relationship of mRNA-1273 (Moderna covid-19 vaccine) is not affected by this report.; Sender's Comments: This case concerns a 98-year-old, male patient with relevant medical history of hypertension, atrial fibrillation, heart catherization, leukemia, who experienced the unexpected event of Death. The event occurred approximately few hours after the first dose of mRNA-1273 (Moderna covid-19 vaccine). The rechallenge was not applicable, as the event happened after the first dose. Though limited information provided such as circumstances surrounding death, cause of death, and autopsy precludes a complete medical and causal assessment of this case; however, this patient's advanced age and multiple underlying medical conditions remains a confounder. The benefit-risk relationship of mRNA-1273 (Moderna covid-19 vaccine) is not affected by this report.; Reported Cause(s) of Death: Unknown cause of death
Narrative:  COVID infection following COVID vaccine series 01/14, Pfizer, dose #1 02/04, Pfizer, dose #2 09/21, Pfizer, dose #3 07/20 CXR Impression: Radiographically stable. No evidence of acute cardiopulmonary process. 08/02 pt cc: cough, chills, fatigue, loss of taste or smell exposure: unknown 08/03 CXR impression: 1. No acute disease in the chest. 2. Status post surgical changes in the left lung. 08/03 ADMIT ED cc: Cough, chest congestion dx: cough, bronchitis LOS: 1 08/17 COVID swab, result: detected 08/17 SARS-COV-2 Variant Sequencing result: pending 09/20 CT Chest W/O impression: 1. Interval development of wispy centrilobular groundglass opacities identified peripherally and exclusively within the RIGHT lung. Given the above history, this could reflect ongoing or resolving COVID pneumonitis. No focal pneumonia or pleural effusion. 2. Status post LEFT upper lobectomy with hyperexpansion LEFT lower lobe in the LEFT hemithorax. The hyperexpanded LEFT lower lobe is clear without suspicious abnormality to indicate COVID pneumonitis or recurrent malignancy. 3. Interval decrease in size of a known metastasis in the inferolateral LEFT pectoralis major muscle since April 2021. LEFT axillary lymph nodes are stable to slightly decreased in short axis diameter since April 2021. Otherwise no thoracic nodal or skeletal metastases.